Multi-strain Probiotics to Prevent Necrotizing Enterocolitis in Very Preterm Infants
Condition(s) studied
Investigational drug(s) / intervention(s)
Multi-strain probiotics: Infants will be started on probiotics (Bifidobacterium and Lacticaseibacillus) with enetral feed.
Study summary
The goal of this clinical trial is to evaluate whether multi-strain probiotics of lactobacillus and bifidobacterium can prevent necrotizing enterocolitis (NEC) in preterm infants born at less than 32 weeks of gestation. The main questions it aims to answer are:
* Does the use of a multi-strain probiotic combination reduce the incidence of NEC in preterm infants?
* Are there any adverse effects associated with the administration of this probiotic combination?
Eligibility
Primary outcome measure(s)
- Incidence of necrotizing enterocolitis (NEC — From date of randomization until the date of 34 weeks corrected gestational age or or date of death from any cause, whichever came first
NEC defined in CNN according to modified Bell's criteria.
Trial sites (4)
| Facility | City | Region | Status |
|---|---|---|---|
| Foothills Medical Center | Calgary | Alberta | |
| Royal Alexandra Hospital | Edmonton | Alberta | |
| Children's and Women's health of Britch Columbia | Vancouver | British Columbia | |
| IWK | Halifax | Canada |
More University of Calgary trials in Canada
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06810154 on ClinicalTrials.gov ↗ ← All trials in Canada